Mass General Brigham Ventures was among the participants in a series A round announced at the launch of the blood stem cell-focused startup.
Garuda Therapeutics, a US-headquartered developer of therapeutics based on blood stem cells, publicly launched yesterday with $72m in series A funding from investors including healthcare provider Mass General Brigham.
Aisling Capital, Northpond Ventures and Orbimed co-led the round, which also featured Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management and National Resilience.
Mass General Brigham participated in the round through strategic investment vehicle Mass General Brigham Ventures.
Garuda is working on technology intended to generate blood…
